Your browser is no longer supported. Please, upgrade your browser.
RPRX Repros Therapeutics Inc. monthly Stock Chart
RPRX [NASD]
Repros Therapeutics Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own0.20% Shs Outstand37.85M Perf Week-12.07%
Market Cap10.45M Forward P/E- EPS next Y-1.01 Insider Trans0.00% Shs Float37.35M Perf Month-25.40%
Income-18.30M PEG- EPS next Q-0.28 Inst Own14.50% Short Float2.62% Perf Quarter-51.86%
Sales- P/S- EPS this Y41.70% Inst Trans-14.80% Short Ratio1.22 Perf Half Y-77.09%
Book/sh-0.01 P/B- EPS next Y5.60% ROA-212.10% Target Price5.50 Perf Year-86.63%
Cash/sh0.10 P/C2.75 EPS next 5Y27.90% ROE-412.40% 52W Range0.27 - 2.47 Perf YTD-79.08%
Dividend- P/FCF- EPS past 5Y7.70% ROI- 52W High-89.02% Beta0.45
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low0.18% ATR0.04
Employees9 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)34.76 Volatility9.82% 10.22%
OptionableYes Debt/Eq- EPS Q/Q56.00% Profit Margin- Rel Volume0.36 Prev Close0.28
ShortableYes LT Debt/Eq- EarningsAug 14 Payout- Avg Volume801.64K Price0.27
Recom2.00 SMA20-16.03% SMA50-30.69% SMA200-73.18% Volume288,846 Change-1.77%
Nov-16-16Upgrade Ladenburg Thalmann Neutral → Buy
Oct-30-15Downgrade BofA/Merrill Neutral → Underperform
May-14-13Reiterated Ascendiant Capital Markets Strong Buy $19 → $23
Mar-28-13Reiterated Ladenburg Thalmann Buy $18 → $25
Nov-15-12Reiterated Ascendiant Capital Markets Strong Buy $12 → $18
Oct-09-12Reiterated Ladenburg Thalmann Buy $15 → $18
Apr-10-12Initiated Ascendiant Capital Markets Strong Buy $6
Mar-16-11Reiterated Ladenburg Thalmann Buy $6 → $9
Aug-14-17 11:24PM  Repros Therapeutics reports 2Q loss Associated Press -10.29%
09:15AM  Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-01-17 04:59PM  Repros (RPRX) Q2 Earnings: What's in Store for the Stock? Zacks
Jul-24-17 01:21PM  Lifshitz & Miller LLP Announces Investigation of Acacia Communications, Inc., AngioDynamics, Inc., ClubCorp Holdings, Inc., HD Supply Holdings, Inc., Ocular Therapeutix, Inc., Repros Therapeutics Inc. and Tahoe Resources Inc. PR Newswire
Jul-18-17 05:50PM  Repros' Proellex Stays on Partial Clinical Hold, Shares Fall Zacks
Jul-17-17 04:17PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc. Business Wire -33.49%
01:01PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX) PR Newswire
12:22PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX PR Newswire
06:30AM  Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA GlobeNewswire
May-18-17 08:45AM  Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock GlobeNewswire -35.08%
May-17-17 04:55PM  Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock GlobeNewswire -5.76%
May-09-17 05:38PM  Repros Therapeutics reports 1Q loss Associated Press
04:01PM  Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results GlobeNewswire
May-05-17 11:02AM  What's in the Cards for Repros (RPRX) this Earnings Season? Zacks
Apr-17-17 09:15AM  Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions GlobeNewswire +10.09%
Apr-11-17 10:21AM  Repros' Proellex Continues to be Under Partial Clinical Hold Zacks
09:40AM  Woodlands drug company names new top exec American City Business Journals
Apr-10-17 09:31AM  Repros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids drug MarketWatch
09:18AM  Repros Names Larry Dillaha, M.D., its Permanent President and CEO GlobeNewswire
09:15AM  Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids GlobeNewswire
Mar-31-17 09:20AM  Repros Therapeutics reports 4Q loss Associated Press
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:15AM  Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
Mar-07-17 09:39AM  Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-02-17 09:22AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
09:15AM  Repros Announces New CEO GlobeNewswire
Jan-30-17 09:15AM  FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids GlobeNewswire
Dec-19-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis GlobeNewswire
Dec-13-16 09:41AM  Repros to Meet with the FDA for Phase III Proellex Program Zacks
06:22AM  How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Insider Monkey
06:22AM  How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers at Insider Monkey
Dec-12-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids GlobeNewswire
Dec-10-16 09:20AM  7 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
09:20AM  7 Companies That Destroyed Shareholders Last Week 24/7 Wall St.
Dec-07-16 12:05PM  Repros Therapeutics Drops on FDA Vote -15.18%
06:02AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Dec-06-16 08:01PM  FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism GlobeNewswire
Dec-05-16 01:05PM  10 Major Pharma and FDA Catalysts Coming in December at 24/7 Wall St. +10.17%
Nov-17-16 01:04PM  REPROS THERAPEUTICS INC. Financials
Nov-16-16 07:01AM  Repros Therapeutics upgraded by Ladenburg Thalmann
Nov-15-16 04:45PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
07:39AM  Repros (RPRX) Reports Positive Top-Line Data on Proellex
Nov-14-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids GlobeNewswire
Nov-09-16 03:32PM  Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus +10.90%
11:11AM  REPROS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 04:06PM  Repros Therapeutics reports 3Q loss
04:01PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:00PM  Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-03-16 06:27PM  What to Expect from Repros (RPRX) This Earnings Season
Oct-10-16 09:20AM  Repros' Secondary Hypogonadism Drug under Review in EU
Oct-05-16 10:42AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure +5.80%
10:35AM  Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities GlobeNewswire
Sep-27-16 01:03PM  Repros Therapeutics, Inc. :RPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 27, 2016
Sep-26-16 09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:15AM  FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism GlobeNewswire
Sep-13-16 09:50AM  Repros Seeks EU Approval for Secondary Hypogonadism Drug
Sep-12-16 04:08PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
11:45AM  Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism GlobeNewswire
Sep-08-16 02:13PM  Why Twitter, AMD and 2 Other Stocks Are in the Red Today, While Repros is Surging at Insider Monkey +9.47%
01:19PM  Heres What Latest Data Could Mean For Repros Therapeutics Inc (RPRX) at Insider Monkey
12:50PM  Why Repros Is Rising
08:56AM  Repros Therapeutics' (RPRX) Proellex Positive in Phase II
Sep-07-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis GlobeNewswire
Aug-18-16 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Aug-16-16 10:39AM  Repros Presents 6-Month Interim Data on Enclomiphene -5.70%
Aug-15-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events
04:01PM  Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men GlobeNewswire
Aug-10-16 07:38AM  Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Aug-09-16 04:24PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:22AM  Repros Therapeutics reports 2Q loss
09:15AM  Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-04-16 08:45AM  Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
Jul-29-16 06:59AM  8 Stocks Under $10 to Trade for Huge Profits +17.78%
Jul-19-16 04:12PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure +16.57%
Jul-01-16 05:19PM  5 Top Biotech Performers of 2016
04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-24-16 08:54AM  Research Report Initiated on Select Biotechnology Equities -7.65%
Jun-07-16 01:44PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Jun-02-16 04:08PM  6 Biotechs Seriously on the Move at 24/7 Wall St. +18.34%
Jun-01-16 04:23PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.65%
04:01PM  Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men GlobeNewswire
May-18-16 04:18PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:01PM  Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids GlobeNewswire
May-16-16 04:56PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:00PM  Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board GlobeNewswire
May-11-16 09:01AM  Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
May-10-16 09:19AM  Repros Therapeutics reports 1Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
09:15AM  Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results GlobeNewswire
May-04-16 08:56AM  Will Repros Therapeutics (RPRX) Continue to Surge Higher? Zacks
May-03-16 09:25AM  Repros (RPRX) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-19-16 10:05AM  These Four Biotech Stocks Are Trading With Massive Volume Today Accesswire +12.19%
Apr-18-16 02:26PM  Why Disney (DIS), Amedica (AMDA), Cvent (CVT), UniPixel (UNXL), and Repros Therapeutics (RPRX) Are Spiking Today at Insider Monkey +22.91%
12:35PM  Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday Accesswire
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
Apr-14-16 03:01PM  Repros to drop testosterone drug in U.S. if key study fails +18.67%
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio include Proellex that is in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis; and enclomiphene, a single isomer of clomiphene citrate, which is in Phase III clinical trials for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The company was founded in 1987 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PODOLSKI JOSEPHPresident and CEODec 09Buy1.6020,00032,000107,422Dec 09 05:13 PM
Masterson Nola EDirectorNov 21Sale1.953,3056,4450Nov 23 04:07 PM